Evidence map›Paper›PMID 34104395›Full record

ArticleTherapeutic advances in endocrinology and metabolism2021

Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial.

Ada S Cheung, Rudolf Hoermann, Jasmine Zhu, Daryl Lim Joon, Jeffrey D Zajac, Mathis Grossmann

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01006395 (Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01006395 phase2 / phase3completednot on this map

Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

TypeinterventionalSponsorAustin HealthRan2011 to 2019Enrolled64ConditionsProstate CancerArmsZoledronic acid, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ada S CheungDepartment of Medicine (Austin Health), The University of Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7158-8804
Rudolf HoermannDepartment of Medicine (Austin Health), The University of Melbourne, VIC, Australia.ORCID https://orcid.org/0000-0002-1326-4270
Jasmine ZhuDepartment of Endocrinology, Austin Health, Heidelberg, VIC, Australia.
Daryl Lim JoonDepartment of Radiation Oncology, Austin Health, Heidelberg, VIC, Australia.
Jeffrey D ZajacDepartment of Medicine (Austin Health), The University of Melbourne, VIC, Australia.
Mathis GrossmannDepartment of Medicine (Austin Health), The University of Melbourne, VIC, Australia.
The University of Melbourne · AUAustin Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnimal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity

methodsThis was a prespecified secondary analysis of an RCT designed to evaluate the effects of zoledronic acid on bone microarchitecture in 76 men with non-metastatic prostate cancer undergoing curative radiotherapy combined with adjuvant ADT (

resultsOver 24 months of ADT, fat mass increased and lean mass decreased for both groups, with no significant between group difference [MAD 401 g (-1307; 2103),

conclusionA single dose of zoledronic acid does not appear to influence glucose metabolism in men newly commencing ADT. Further study to evaluate the endocrine relationship between bisphosphonates, bone and glucose metabolism is required. TRIAL REGISTRATION NUMBER: [ClinicalTrials.gov identifier: NCT01006395].

Indexed as

androgen deprivationbisphosphonatesdiabetesinsulin resistanceprostate cancer

Identifiers

PMID34104395
PMCPMC8111529
OpenAlexW3159659913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.